Company Watch

Ipca launches new pain manager

Our News Bureau - Mumbai

Ipca Laboratories has just launched India's first Etodolac, called Etova, which is a new generation pain manager that is considerably safer than Coxibs, which have been linked to cardiovascular side-effects. Etova is a preferential COX II inhibitor, and is a safe and effective pain relieving agent. It is also US FDA approved. Pain management is a growing area of activity, with the increased incidence of dental pain, arthritis pain, lower back pain, injuries, and post surgical pain. Conventional pain killers have been found wanting in treating pain due to their high rate of gastric side effects. Coxibs, or non-steroidal anti-inflammatory drugs, were launched to overcome these side effects of conventional pain killers. Ipca was the first in India to also introduce other pain managers like Zerodol and Movon (Aceclofenac), and also HCQS (Hydroxychloroquine). With the launch of Etova, India's first Etodolac, Ipca will be consolidating its position in the pain management category.